![Sutherland Kester Maciver](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sutherland Kester Maciver
Corporate Officer/Principal en The University of Edinburgh .
Cargos activos de Sutherland Kester Maciver
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
The University of Edinburgh | Corporate Officer/Principal | 14/06/2010 | - |
Historial de carrera de Sutherland Kester Maciver
Antiguos cargos conocidos de Sutherland Kester Maciver.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Amoebics Ltd.
![]() Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Director Técnico/Científico/I+D | 01/01/1998 | 10/07/2013 |
Fundador | 23/11/2009 | 10/07/2013 |
Estadísticas
Internacional
Reino Unido | 3 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Amoebics Ltd.
![]() Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Health Technology |